NCT03521895View on ClinicalTrials.gov

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

CompletedOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Macular Degeneration
Interventions
DRUG

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Patients observed with regular and irregular treatment course

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03521895 - An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies | Biotech Hunter | Biotech Hunter